BioSpace News Archive

7 Hills Pharma, a clinical stage immunotherapy company focused on development of drugs for the treatment and prevention of cancer and infectious diseases, announced that it has launched a coronavirus vaccine program for older adults.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that it will hold a conference call for investors on Wednesday, April 29, 2020, at 5:00 p.m. Eastern Time.

Mersana Therapeutics, Inc. today announced the appointment of Martin H. Huber, M.D., to its Board of Directors, effective immediately. “We are extremely excited to bring in a new board member with such deep experience in oncology drug developmen

– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session –

Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it will host an investor conference call and webcast on two studies evaluating its investigational drug, FINTEPLA®, in Dravet syndrome and Sunflower syndrome, on Wednesday, April 22, 2020, at 1:00 PM ET. Stephen J. Farr, Ph.D., President and CEO of Zogenix, will join Joseph Sullivan, M.D., UCSF Benioff Children’s Hospital

CNS Pharmaceuticals, Inc. announced that CEO, John M. Climaco, will be issuing a shareholder webinar on April 22nd, 2020 at 4:30pm ET to discuss the Company’s novel DNA-binding agent, WP1244, and to provide an update on both the development of WP1122 through its strong relationship with WPD Pharmaceuticals in Poland, and a glioblastoma survivor treated with Berubicin.

Coherus BioSciences, Inc., announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.500% convertible senior subordinated notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced the pricing of an underwritten public offering of 7,150,000 shares of its common stock at a price to the public of $14.00 per share.

The Dynamic Ventilator Reserve Plan Will Leverage Cohealo’s Platform in Partnership with the American Hospital Association, FEMA, and Leading Group Purchasing Organizations to Track National Ventilator Availability and Ease Critical Shortages by Sharing Between Health Systems

Stem cells are controversial but also quite significant and over the period stated 2019 to 2029 will see an impressive growth in demand.